By inhibiting the activity of mutant IDH enzymes, vorasidenib enables the reactivation of α-ketoglutarate-dependent pathways, such as DNA and histone demethylation, improvement in mitochondrial homeostasis, and partial restoration of differentiation capacity in glioma cells [24,27,28]. Here, IDH2 is linked to central nervous system cancer.